NO20091045L - 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler - Google Patents

3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Info

Publication number
NO20091045L
NO20091045L NO20091045A NO20091045A NO20091045L NO 20091045 L NO20091045 L NO 20091045L NO 20091045 A NO20091045 A NO 20091045A NO 20091045 A NO20091045 A NO 20091045A NO 20091045 L NO20091045 L NO 20091045L
Authority
NO
Norway
Prior art keywords
hdl cholesterol
angioplasty
pyridinecarboxamide
increasing agents
pyrazinecarboxamide derivatives
Prior art date
Application number
NO20091045A
Other languages
English (en)
Inventor
Paul Hebeisen
Stephan Roever
Matthias Heinrich Nettekoven
Ulrike Obst Sander
Mirjana Andjelkovic
Agnes Benardeau
Evelyne Chaput
Constantinos G Panousis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091045L publication Critical patent/NO20091045L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av forbindelser med formelen hvor A, G, R1 til R8 og R17 er som definert i beskrivelsen, for fremstilling av medikamenter for behandling og/eller forebygging av sykdommer som kan behandles med HDL-kolesterol-økende midler, så som perifer vaskulær sykdom, dyslipidemi, hyperbetalipoproteinemi, hypoalfalipoproteinemi, hyperkolesterolemi, hypertriglyceridemi, familiær hyperkolesterolemi, kardiovaskulære lidelser, angina, ischemi, hjerte-ischemi, slag, myokardialt infarkt, reperfusjonsskade, angioplastisk restenose, hypertensjon og vaskulære komplikasjoner ved diabetes, fedme eller endotoksemi.
NO20091045A 2006-10-04 2009-03-10 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler NO20091045L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121755 2006-10-04
PCT/EP2007/060094 WO2008040651A1 (en) 2006-10-04 2007-09-24 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Publications (1)

Publication Number Publication Date
NO20091045L true NO20091045L (no) 2009-03-31

Family

ID=38740266

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091045A NO20091045L (no) 2006-10-04 2009-03-10 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Country Status (14)

Country Link
US (3) US20080085906A1 (no)
EP (2) EP2074096B1 (no)
JP (1) JP2010505789A (no)
KR (1) KR101107896B1 (no)
CN (1) CN101522626A (no)
AU (1) AU2007304365A1 (no)
BR (1) BRPI0717845A2 (no)
CA (1) CA2664119A1 (no)
IL (1) IL197577A0 (no)
MX (1) MX2009003222A (no)
NO (1) NO20091045L (no)
RU (1) RU2454405C2 (no)
WO (1) WO2008040651A1 (no)
ZA (1) ZA200902353B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587106A (en) 2004-12-14 2012-03-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20100099738A (ko) 2007-12-20 2010-09-13 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
US7897621B2 (en) * 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
JP5702293B2 (ja) 2008-11-10 2015-04-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
MX2011006503A (es) 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
BRPI1016109A2 (pt) 2009-06-19 2016-05-17 Astrazeneca Ab "composto, composição farmacêutica, e, processo para preparar um composto"
UA107088C2 (xx) 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2569289A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG185524A1 (en) 2010-05-12 2012-12-28 Vertex Pharma Compounds useful as inhibitors of atr kinase
CA2798760A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) * 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2014001862A (es) * 2011-09-12 2014-05-30 Hoffmann La Roche 5-cicloalquil-o 5-heterociclil-nicotinamidas.
CA2844835A1 (en) * 2011-09-12 2013-03-21 Uwe Grether N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
CN103781765A (zh) * 2011-09-12 2014-05-07 霍夫曼-拉罗奇有限公司 作为hdl-胆固醇升高剂的3-吡啶甲酰肼类
MX353461B (es) 2011-09-30 2018-01-15 Vertex Pharma PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR).
KR102056586B1 (ko) 2011-09-30 2019-12-18 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2850564A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
CA2880477A1 (en) * 2012-08-23 2014-02-27 F. Hoffmann-La Roche Ag Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
HUE055618T2 (hu) 2012-12-07 2021-12-28 Vertex Pharma 2-amino-N-(piperidin-1-il-piridin-3-il)-pirazolo-[1,5-alfa]-pirimidin-3-karboxamid, mint atr-kináz inhibítoraként használható vegyület
RU2668073C2 (ru) * 2013-03-14 2018-09-26 Дарт Нейросайенс (Кайман) Лтд. Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
RU2020110358A (ru) 2014-06-05 2020-04-30 Вертекс Фармасьютикалз Инкорпорейтед Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
MX2017007874A (es) * 2014-12-24 2018-01-24 Lg Chemical Ltd Derivado de biarilo como agonista de gpr120.
EP3351533A4 (en) 2015-09-18 2019-03-06 Kaken Pharmaceutical Co., Ltd. BIARY DERIVATIVE AND MEDICAMENT THEREOF
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
PL237374B1 (pl) * 2017-11-10 2021-04-06 Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie
WO2024003259A1 (en) * 2022-06-30 2024-01-04 Bayer Aktiengesellschaft Tead inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104332D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
WO2004111033A1 (en) 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
CA2602787C (en) 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
DE602007006531D1 (de) * 2006-10-04 2010-06-24 Hoffmann La Roche Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
RU2009116670A (ru) 2010-11-10
EP2450350A1 (en) 2012-05-09
RU2454405C2 (ru) 2012-06-27
CN101522626A (zh) 2009-09-02
KR20090075852A (ko) 2009-07-09
US8188093B2 (en) 2012-05-29
MX2009003222A (es) 2009-04-06
IL197577A0 (en) 2009-12-24
WO2008040651A1 (en) 2008-04-10
US20090143409A1 (en) 2009-06-04
JP2010505789A (ja) 2010-02-25
EP2074096A1 (en) 2009-07-01
AU2007304365A1 (en) 2008-04-10
US20080085906A1 (en) 2008-04-10
ZA200902353B (en) 2010-04-28
KR101107896B1 (ko) 2012-01-25
US20100267745A1 (en) 2010-10-21
EP2074096B1 (en) 2012-06-27
US7812028B2 (en) 2010-10-12
CA2664119A1 (en) 2008-04-10
BRPI0717845A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
NO20091045L (no) 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler
IN2012DN00766A (no)
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
WO2012104263A3 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
IN2012DN03043A (no)
MX2013010795A (es) 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2).
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
WO2010057101A3 (en) Compounds useful as hiv blockers
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
WO2008127682A3 (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
PH12015500471A1 (en) Therapeutic agent for dyslipidemia
WO2006103120A3 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application